Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Distribution of clinical and MR imaging findings with respect to the duration of toluene abuse
Duration of Abuse (y) No. of Patients Symptoms^* Neurologic Signs^* Cases with Positive MR Imaging Finding (n)
White Matter Changes Thalamic Hypointensity Thin Corpus Callosum
Restricted Diffuse
1 8 IS (5), FG (4), ANS (5), TN (1) None 0 0 0 0
2 4 IS (4), FG (3), ANS (3), TN (1) None 0 0 0 0
3 3 IS (2), FG (3), ANS (2) ATX (2) 1 0 0 0
4 5 IS (5), FG (5), ANS (3) ATX (2), TM (2), SP (1) 3 0 0 0
5 6 IS (4), FG (5), ANS (3), TN (3) ATX (1), TM (1) 1 0 0 1
6 4 IS (3), FG (3), ANS (3), TN (3) ATX (3), TM (2) 1 2 1 1
7 3 IS (3), FG (3), ANS (3), TN (2) ATX (3), TM (3), SP (2), DA (1) 1 2 2 2
8 4 IS (4), FG (4), ANS (4), TN (2) ATX (4), TM (3), SP (3), NYS (1), DA (1) 2 2 2 2
9 3 IS (3), FG (3), ANS (3), TN (2) ATX (3), TM (3), SP (3), NYS (1), DA (1) 1 2 2 2
11 1 IS, FG, ANS, TN ATX, TM, SP, NYS, DA 0 1 1 1
* ANS indicates anosmia; ATX, ataxia; DA, dysarthria; FG, forgetfulness; IS, insomnia; NYS, nystagmus; SP, spasticity; TM, tremors; and TN, tinnitus. Numbers in parentheses the number of cases.

Duration of Abuse (y)	No. of Patients	Symptoms^*	Neurologic Signs^*	Cases with Positive MR Imaging Finding (n)
				White Matter Changes		Thalamic Hypointensity	Thin Corpus Callosum
				Restricted	Diffuse	Thalamic Hypointensity	Thin Corpus Callosum
1	8	IS (5), FG (4), ANS (5), TN (1)	None	0	0	0	0
2	4	IS (4), FG (3), ANS (3), TN (1)	None	0	0	0	0
3	3	IS (2), FG (3), ANS (2)	ATX (2)	1	0	0	0
4	5	IS (5), FG (5), ANS (3)	ATX (2), TM (2), SP (1)	3	0	0	0
5	6	IS (4), FG (5), ANS (3), TN (3)	ATX (1), TM (1)	1	0	0	1
6	4	IS (3), FG (3), ANS (3), TN (3)	ATX (3), TM (2)	1	2	1	1
7	3	IS (3), FG (3), ANS (3), TN (2)	ATX (3), TM (3), SP (2), DA (1)	1	2	2	2
8	4	IS (4), FG (4), ANS (4), TN (2)	ATX (4), TM (3), SP (3), NYS (1), DA (1)	2	2	2	2
9	3	IS (3), FG (3), ANS (3), TN (2)	ATX (3), TM (3), SP (3), NYS (1), DA (1)	1	2	2	2
11	1	IS, FG, ANS, TN	ATX, TM, SP, NYS, DA	0	1	1	1